Synonyms: ecteinascidin 743 | ET-743 | Yondelis®
trabectedin is an approved drug (EMA (2007), FDA (2015))
Compound class:
Natural product
Comment: The ecteinascidins (Ets) are natural products derived from the marine tunicate Ecteinascidia turbinata. Being a natural substance, there is some ambiguity in the literature as to the exact chemical structure of trabectedin, therefore representations of the compound on the external resource links may vary slightly from that shown here. Trabectedin is now produced synthetically. Mechanistically trabectedin is a DNA minor groove binder and it forms covalent bonds with the exocyclic amino group of certain guanines in the minor groove and interstrand crosslinks via van der Waals interactions and hydrogen bonds [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Used in the treatment of soft tissue sarcoma and ovarian cancer. In October 2015, the US FDA approved trabectedin for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have already received an anthracycline-containing chemotherapy (e.g. doxorubicin, gemcitabine, docetaxel or ifosfamide). |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Interrupts the cell cycle and nucleotide excision repair process in cancer cells. For a complete overview of the mechanism of action of trabectedin, see the DrugBank link on the Summary tab of this ligand page and the review by D'Incalci and Galmarini (2010) [1]. Due to the complex and varied nature of nucleic acids we do not include DNA or RNA as targets on this database. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |